Dr. Dupré is a neurologist at the CHU de Québec-Laval University, an Associate Professor in the Department of Medicine of the School of Medicine (Laval University), and the Director of the Neuromuscular and Neurogenetic Disease Clinic of the CHU de Québec – Université Laval.
Dr. Dupré completed his medical training at McGill University and his residency in neurology at Laval University. He completed his postdoctoral training at the Montreal Neurological Hospital and Institute and at Harvard University. In 2007, he discovered a gene (syne-1) implicated in a new form of hereditary ataxia that has since been highly recognized internationally. Dr. Dupré also played an important role in the discovery of the involvement of the TARDBP in the etiology of amyotrophic lateral sclerosis. He is now involved in several provincial, national, and international networks that contribute to the discovery of genes involved in neurological diseases. He has generated more than 100 original publications. Dr. Dupré’s remarkable achievements have earned him several awards, including the 2015 Quebec Society of Muscular Dystrophy Award – ALS component – related to his involvement in the Clinic for Neuromuscular and Neurogenetic Diseases.
The research component of the clinic has grown significantly in recent years, with the creation of the Québec Parkinson Network (rpq-qpn.ca). The network connects clinicians with basic science researchers in the field, giving access to a registry of nearly 1000 patients. In addition to his clinical program, Dr. Dupré is involved in research projects linking clinical and basic research. This is done in collaboration with Dr. François Gros-Louis, of the LOEX research center at CHU de Québec – Laval University. One of these projects aims to discover biomarkers of amyotrophic lateral sclerosis in the skin. Another important project Dr. Dupré takes part in focuses on the development of a reconstructed skin model to study neurofibromatosis. Finally, Dr. Dupré is actively collaborating with Dr. Gros-Louis to identify pathogenic mechanisms of intracranial aneurysms in the Inuit and French-Canadian populations and to develop in vitro models of the disease. This project has just been funded by CIHR for a duration of 5 years.
Département des sciences neurologiques
Canada G1J 1Z4
Data not available
- Beaudin, MarieMaster studentHôpital de l'Enfant-Jésus+1 418-649-0252, extension firstname.lastname@example.org
1401, 18e Rue
Canada G1J 1Z4
- Franche, Lily-AnnEmployeeLily-Ann.Franche@crchudequebec.ulaval.ca
- Gravel, ManonEmployeeHôpital de l'Enfant-Jésus+1 418-649-0252, extension email@example.com
1401, 18e Rue
Canada G1J 1Z4
The GBA p.Trp378Gly mutation is a probable French-Canadian founder mutation causing Gaucher disease and synucleinopathies.Journal Article
Clin Genet, 94 (3-4), pp. 339-345, 2018, ISSN: 0009-9163.
Sequencing of the GBA coactivator, Saposin C, in Parkinson disease.Journal Article
Neurobiol Aging, 2018, ISSN: 0197-4580.
Effects of Antiparkinson Medication on Cognition in Parkinson's Disease: A Systematic Review.Journal Article
Can J Neurol Sci, 45 (4), pp. 375-404, 2018, ISSN: 0317-1671.
Genome-wide association analysis identifies new candidate risk loci for familial intracranial aneurysm in the French-Canadian population.Journal Article
Sci Rep, 8 (1), pp. 4356, 2018, ISSN: 2045-2322.
TOX3 Variants Are Involved in Restless Legs Syndrome and Parkinson's Disease with Opposite Effects.Journal Article
J Mol Neurosci, 64 (3), pp. 341-345, 2018, ISSN: 0895-8696.
- Canadian Consortium on Neurodegeneration in Aging - Full proposal, Subvention, Instituts de recherche en santé du Canada, Consortium canadien en neurodégénérescence et vieillissement (CCNV), from 2014-04-01 to 2019-03-31
- Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Centre thématique de recherche en neurosciences, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1999-06-01 to 2020-10-18
- Pathogenic Pathways and in-vitro modelization of Intracranial Aneurysms in populations of Inuit and French Canadian descent, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2017-04-01 to 2022-03-31
Recently finished projects
- A patient-derived hiPSC neuronal platform for drug discovery in Parkinson's disease and amyotrophic lateral sclerosis, Subvention, Consortium québécois sur la découverte du médicament, from 2016-07-22 to 2018-03-15
- Development of a tissue-engineered skin model derived from NF1 patients to study tumor genesis and to predict response to therapy, Subvention, Hospital for Sick Children Research Institute (The), from 2016-02-01 to 2017-03-31
- Emerging Team to identify and characterize novel and existing Hereditary Spastic Paraplegia (HSP) disease genes, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2012-02-01 to 2017-01-31
- Human inducible pluripotent stem cells (IPSC) plateform, Subvention, La Fondation Neuro Canada / Brain Canada, Soutien aux plateformes technologiques (SSPT), from 2015-04-01 to 2018-03-31
- Project MindE, Subvention, Brain Canada Foundation, from 2017-08-01 to 2017-10-01
- Réseau Parkinson Québec / Quebec Parkinson Network, Subvention, Fonds de recherche du Québec - Santé, Réseaux thématiques de recherche, from 2016-04-01 to 2018-03-31